Loading
A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, now recruiting.
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer is a phase 2 interventional study registered as NCT06567782 by GlaxoSmithKline, with 120 participants planned, started 2025-02-18 and due to reach its primary completion in 2026-11-23. Interventions recorded: Dostarlimab and CAPEOX.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Colorectal cancer and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/